Castleark Management’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
Castleark Management's KYMR Position: Q3 2026 in Review
Castleark Management opened a new position in Kymera Therapeutics (KYMR) in Q3 2026: 23,790 shares worth $2.66M. The stake represents 0.07% of the portfolio and ranks #195 among its holdings.
301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- Castleark Management held 23,790 shares of Kymera Therapeutics worth $2.66M as of Q3 2026.
- Kymera Therapeutics was a new Castleark Management position in Q3 2026.
- Kymera Therapeutics made up 0.07% of Castleark Management's portfolio in Q3 2026, its #195 holding.
- 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on Castleark Management's 13F filing for Q3 2026, filed 16 Nov 2026.